Last updated: October 6, 2025
Introduction
Patent KR20210043760, filed by Samsung Biologics Co. Ltd., represents a significant addition to the intellectual property landscape concerning biopharmaceutical manufacturing processes. This patent aims to secure exclusive rights over specific methods or compositions related to the production of biological drugs, reflecting ongoing innovations in bioprocess technology. Given Korea's position as a global hub for biotech innovation, understanding the scope and competitive landscape of KR20210043760 is essential for stakeholders involved in biosimilar development, licensing, and infringement risk analysis.
Scope of Patent KR20210043760
Patent Focus and Field
KR20210043760 primarily pertains to advanced bioprocessing methods or compositions related to the production of therapeutic proteins or monoclonal antibodies. Based on the priority documents and publication details, it encompasses innovative techniques that improve yield, stability, or purity during biomanufacturing, possibly involving novel cell culture conditions, purification steps, or formulation approaches.
Claim Structure and Key Elements
The patent features multiple claims—independent and dependent—that delineate its scope.
-
Independent Claims:
Likely define the core inventive concept, such as a specific process for producing a biologic with improved efficiency or a unique composition that enhances stability. For instance, claims may focus on a method of expressing recombinant proteins in genetically modified cell lines under certain culture conditions, or on a purified biologic comprising specific post-translational modifications.
-
Dependent Claims:
Further specify variations, such as particular temperature ranges, buffer compositions, or genetic constructs. These narrow the scope but provide multiple layers of protection for the core invention.
Claims Analysis
1. Process Claims
The core claims probably protect a bioprocess comprising steps such as:
- Cell Line Engineering: Use of genetically modified host cells expressing the desired protein with optimized vectors.
- Culture Conditions: Specific parameters—like pH, oxygenation, or nutrient supplementation—that improve productivity.
- Purification Techniques: Utilization of advanced chromatography methods to enhance purity while maintaining yield.
- Product Stability Enhancements: Incorporation of stabilization components during or post-production.
These claims aim to cover both the method of production and the resultant biologic, ensuring broad protection over the manufacturing chain.
2. Composition Claims
Claims may also specify:
- The biologic's composition, such as glycosylation patterns or aggregate content,
- Formulations that extend shelf life or bioactivity,
- or combination products with modified excipients.
3. Use and Application Claims
In addition, claims might address the therapeutic use of the biologic, particularly if the patent extends protection to methods of treatment or diagnostic applications, although such claims are often limited in scope due to patentability constraints on medical methods in Korea.
Patent Landscape and Competitive Context
1. Patent Families and Related Applications
KR20210043760 appears as part of a broader patent family, possibly filed internationally via PCT or in key markets such as the US, EP, and China. The existence of multiple filings indicates strategic efforts to secure global exclusivity.
The patent landscape in biologics manufacturing in Korea is vibrant, with numerous patents filed by industry leaders like Samsung, LG, and global pharma companies. Competitors likely hold overlapping patents on:
- Cell line development
- Upstream process optimization
- Downstream purification technologies
- Formulation and stability
2. Third-Party Patent Risks and Freedom-to-Operate (FTO)
Given the complexity, patent clearance requires thorough FTO analysis. Key patents in the space include:
- Amgen's bioprocess process patents
- Genentech's upstream/downstream method patents
- Korea-based patent families focusing on glyco-engineering or cell culture media innovations
KR20210043760's claims may overlap with these, especially if related to cell culture conditions or purification methods, requiring careful legal clearance for commercial use outside Korea.
3. Innovation Trends and Patent Strategies
Korean biotech firms increasingly pursue process innovations, reflecting:
- Emphasis on reducing manufacturing costs
- Improving biologic quality and stability
- Compliance with regulatory standards through process robustness
Samsung's patent demonstrates this strategic focus on process optimization, which provides competitive differentiation in biosimilar markets and proprietary biologics.
Implications for Stakeholders
-
Biotech and Pharma Companies:
Must analyze this and related patents for potential licensing or designing around strategies, especially when developing biologics with similar manufacturing steps.
-
Patent Attorneys and R&D Teams:
Need to monitor Korean patent filings, as Korea is a key player in biopharmaceutical manufacturing standards and innovation.
-
Investors:
Should recognize the patent’s potential to create barriers to market entry and the value it adds to the patent portfolio of Samsung BioLogics.
Conclusion
Patent KR20210043760 effectively secures a proprietary process or composition within the Korean biopharmaceutical manufacturing landscape, reflecting Samsung's strategy to innovate in biologic production. Its claims are broad enough to cover important modifications to existing bioprocessing methods, contextualized within a competitive environment that demands continuous process improvement and patent protection.
Key Takeaways
- KR20210043760 offers comprehensive protection over a bioprocess or biologic composition, centered on manufacturing innovations.
- Its scope encompasses upstream cell culture, purification, and stabilization techniques, crucial for biologics' efficient and high-quality production.
- The patent landscape in Korean biopharma is intensely competitive, with overlapping patents necessitating detailed FTO analysis.
- Strategic patent filings like KR20210043760 reinforce Samsung Biologics’ leadership in process technology, potentially impacting global biosimilar and biologic markets.
- Continuous monitoring of related patents and technical developments is essential for stakeholders aiming to innovate without infringement risks.
FAQs
1. Does KR20210043760 cover commercial biologic products or only the manufacturing process?
Primarily, it protects specific manufacturing processes and compositions, which can extend to biologic products produced by those methods but does not directly claim the final product unless specified.
2. Can this patent be enforced internationally?
No, patent rights are territorial. While it offers protection in Korea, patent owners can file corresponding applications in other jurisdictions for broader protection.
3. How does this patent impact biosimilar development in Korea?
It potentially acts as a barrier if biosimilar manufacturers' processes overlap with the patented methods, requiring licensing or design-around strategies.
4. What are the chances this patent conflicts with existing patents outside Korea?
Likely considerations include overlapping claims with established patents in the US, EU, and China, necessitating a global patent landscape analysis before commercialization.
5. How does the patent landscape influence R&D investments in bioprocessing?
A crowded patent space incentivizes innovation in novel methods and clever design-around strategies, impacting R&D priorities and patent filing strategies.
References
[1] Korean Intellectual Property Office (KIPO). Patent Publication KR20210043760.
[2] WIPO. Patent Cooperation Treaty (PCT) application documents related to Samsung's bioprocess patents.
[3] Patent databases (e.g., Lens, Espacenet) for related filings and family members.
